Novo Nordisk (Ozempic)
Acquired
Profitability and Innovation in Pharma
This chapter explores the complexities of profitability in the pharmaceutical sector, focusing on the high investment in research and development necessary for drug creation. It contrasts the performance of top companies like Novo Nordisk with declining trends in the overall industry and examines the roles of insurers and pharmacy benefit managers in the healthcare ecosystem. Through discussions on GLP-1 medications and their market potential, it questions the sustainability of profits driven by competition and innovation in the pharmaceutical space.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
